Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes
Само за регистроване кориснике
2010
Аутори
Rizzo, ManfrediVekić, Jelena
Koulouris, Spyridon
Zeljković, Aleksandra
Jelić-Ivanović, Zorana
Spasojević-Kalimanovska, Vesna
Rini, Giovam Battista
Sakellariou, Dimitrios
Pastromas, Socrates
Mikhailidis, Dimitri P.
Manolis, Antonis S.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbAlc] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic c...hanges in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established.
Кључне речи:
Rosiglitazone / diabetes / low-density lipoproteins / high-density lipoproteins / size / subclassesИзвор:
Angiology, 2010, 61, 6, 584-590Издавач:
- Sage Publications Inc, Thousand Oaks
Финансирање / пројекти:
- Испитивање биохемијских и генетичких фактора ризика као узрочника и маркера атеросклерозе и других обољења: аналитички и клинички аспекти (RS-MESTD-MPN2006-2010-145036)
DOI: 10.1177/0003319710366431
ISSN: 0003-3197
PubMed: 20462890
WoS: 000279760800011
Scopus: 2-s2.0-77955033179
Институција/група
PharmacyTY - JOUR AU - Rizzo, Manfredi AU - Vekić, Jelena AU - Koulouris, Spyridon AU - Zeljković, Aleksandra AU - Jelić-Ivanović, Zorana AU - Spasojević-Kalimanovska, Vesna AU - Rini, Giovam Battista AU - Sakellariou, Dimitrios AU - Pastromas, Socrates AU - Mikhailidis, Dimitri P. AU - Manolis, Antonis S. PY - 2010 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1398 AB - Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbAlc] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic changes in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established. PB - Sage Publications Inc, Thousand Oaks T2 - Angiology T1 - Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes VL - 61 IS - 6 SP - 584 EP - 590 DO - 10.1177/0003319710366431 ER -
@article{ author = "Rizzo, Manfredi and Vekić, Jelena and Koulouris, Spyridon and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Rini, Giovam Battista and Sakellariou, Dimitrios and Pastromas, Socrates and Mikhailidis, Dimitri P. and Manolis, Antonis S.", year = "2010", abstract = "Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbAlc] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic changes in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established.", publisher = "Sage Publications Inc, Thousand Oaks", journal = "Angiology", title = "Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes", volume = "61", number = "6", pages = "584-590", doi = "10.1177/0003319710366431" }
Rizzo, M., Vekić, J., Koulouris, S., Zeljković, A., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V., Rini, G. B., Sakellariou, D., Pastromas, S., Mikhailidis, D. P.,& Manolis, A. S.. (2010). Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. in Angiology Sage Publications Inc, Thousand Oaks., 61(6), 584-590. https://doi.org/10.1177/0003319710366431
Rizzo M, Vekić J, Koulouris S, Zeljković A, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Rini GB, Sakellariou D, Pastromas S, Mikhailidis DP, Manolis AS. Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. in Angiology. 2010;61(6):584-590. doi:10.1177/0003319710366431 .
Rizzo, Manfredi, Vekić, Jelena, Koulouris, Spyridon, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Rini, Giovam Battista, Sakellariou, Dimitrios, Pastromas, Socrates, Mikhailidis, Dimitri P., Manolis, Antonis S., "Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes" in Angiology, 61, no. 6 (2010):584-590, https://doi.org/10.1177/0003319710366431 . .